A number of other equities analysts have also issued reports on the company. Credit Suisse Group reissued a buy rating and issued a $36.00 price objective on shares of Coherus Biosciences in a report on Friday, November 8th. Zacks Investment Research raised Coherus Biosciences from a hold rating to a buy rating and set a $18.00 price objective for the company in a report on Thursday, November 7th. HC Wainwright reissued a buy rating and issued a $29.00 price objective on shares of Coherus Biosciences in a report on Monday, November 25th. ValuEngine lowered Coherus Biosciences from a sell rating to a strong sell rating in a report on Thursday, October 10th. Finally, TheStreet raised Coherus Biosciences from a d- rating to a c- rating in a report on Thursday, November 7th. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $30.29.
NASDAQ:CHRS opened at $19.89 on Friday. The firm has a market capitalization of $1.39 billion, a PE ratio of -6.18 and a beta of 2.89. The stock has a 50 day moving average of $18.13 and a 200-day moving average of $19.25. Coherus Biosciences has a 52 week low of $10.83 and a 52 week high of $23.91. The company has a current ratio of 3.34, a quick ratio of 3.25 and a debt-to-equity ratio of 3.37.
In other Coherus Biosciences news, COO Vincent R. Anicetti sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $18.69, for a total value of $46,725.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Jean-Frederic Viret sold 3,112 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $18.88, for a total value of $58,754.56. The disclosure for this sale can be found here. Insiders sold 837,659 shares of company stock valued at $15,091,914 over the last 90 days. 18.20% of the stock is currently owned by insiders.
Several large investors have recently made changes to their positions in CHRS. Cutler Group LP acquired a new stake in shares of Coherus Biosciences during the 3rd quarter valued at $32,000. Tower Research Capital LLC TRC acquired a new stake in shares of Coherus Biosciences during the 3rd quarter valued at $52,000. Hoey Investments Inc. acquired a new stake in shares of Coherus Biosciences during the 4th quarter valued at $66,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Coherus Biosciences during the 2nd quarter valued at $75,000. Finally, Bank of Montreal Can acquired a new stake in shares of Coherus Biosciences during the 2nd quarter valued at $114,000. Institutional investors own 98.62% of the company’s stock.
About Coherus Biosciences
Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.
Featured Article: What is a Tariff?
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.